Effects of eplerenone on cardiovascular and metabolic disorders in patients with primary aldosteronism

Effects of eplerenone on cardiovascular and metabolic disorders in patients with primary aldosteronism - Effects of aldosterone blockade in patients with primary aldosteronism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004581

Enrollment

100

Registered

2011-02-01

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

essential hypertension, primary aldosteronism

Interventions

Eplerenone 50-100mg/d (12-month administration)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Essential hypertension and primary aldosteronism diagnosed by the JSH2009 Guideline

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating women 2. malignant hyperension 3. secondary hypertension except for primary aldosteronism 4. diabetes mellitus patients with unstable glycemic control whose HbA1c is more than 8%, or complicated with diabetic nephropathy more than stage 2. 5. patients whose serum triglycemide is more than 400mg/dL 6. patient who is intolerate or allergic agiansts eplerenone and amlogipine 7. patient whose renal function (estimated GFR) is less than 50mL/min. 8. patient whose serum potassium level is more than 5.0mEq/L 9. patinet who sufferd from severe hepatic injury

Design outcomes

Primary

Measure	Time frame
blood pressure	—

Secondary

Measure	Time frame
cardiovascular and renal injuries, metaboloc disorders	—

Countries

Japan

Contacts

Public ContactYoshiyu Takeda

Kanazawa University Hospital Department of Endocrinology and Metabolism

takeday@med.kanazawa-u.ac.jp076-265-2252

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026